Tracheostomy Before Polatuzumab Vedotin-Containing Therapy for Airway-Threatening Cervical Diffuse Large B-Cell Lymphoma: A Case Report of Two Patients.

IF 0.7 Q4 HEMATOLOGY
Case Reports in Hematology Pub Date : 2026-09-28 eCollection Date: 2026-01-01 DOI:10.1155/crh/4447338
Yoshikazu Ikoma, Nobuhiro Kanemura, Rinto Otsuka, Daisuke Okamoto, Naoki Hayase, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Takenori Ogawa, Masahito Shimizu
{"title":"Tracheostomy Before Polatuzumab Vedotin-Containing Therapy for Airway-Threatening Cervical Diffuse Large B-Cell Lymphoma: A Case Report of Two Patients.","authors":"Yoshikazu Ikoma, Nobuhiro Kanemura, Rinto Otsuka, Daisuke Okamoto, Naoki Hayase, Takuro Matsumoto, Nobuhiko Nakamura, Hiroshi Nakamura, Takenori Ogawa, Masahito Shimizu","doi":"10.1155/crh/4447338","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Bulky cervical diffuse large B-cell lymphoma (DLBCL) with impending airway compromise presents an urgent management dilemma, particularly when diagnostic confirmation and timely initiation of definitive therapy must be balanced against the risk of abrupt airway deterioration. Evidence guiding airway-first management before polatuzumab vedotin-containing frontline therapy remains limited.</p><p><strong>Case presentation: </strong>We describe two older men with bulky cervical DLBCL who presented with progressive airway-related symptoms and marked upper airway narrowing on endoscopic and radiologic evaluations. In both cases, semiurgent tracheostomy was prioritized over emergent radiotherapy or immediate systemic therapy, allowing pathological confirmation and treatment planning under controlled conditions. After DLBCL was pathologically confirmed, full-dose polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) were initiated 15 and 10 days after tracheostomy, respectively, and delivered without dose reduction or treatment delay. No perioperative or tracheostomy-site complications occurred. Both patients completed six cycles of Pola-R-CHP followed by two cycles of rituximab. One patient achieved a partial metabolic response; after receiving salvage chemoimmunotherapy followed by CD19-directed chimeric antigen receptor T-cell therapy, he achieved a complete metabolic response. In the other patient, residual fluorodeoxyglucose uptake without corresponding structural lesions was managed with close surveillance after negative follow-up evaluations, including laryngoscopy and thyroid fine-needle aspiration.</p><p><strong>Conclusions: </strong>Although limited to two patients, these cases suggest that proactive airway stabilization can create a controlled window for diagnosis and treatment planning and may facilitate safe delivery of full-dose Pola-R-CHP in selected patients with airway-threatening cervical DLBCL.</p>","PeriodicalId":46307,"journal":{"name":"Case Reports in Hematology","volume":"2026 ","pages":"4447338"},"PeriodicalIF":0.7000,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13620398/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/crh/4447338","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Bulky cervical diffuse large B-cell lymphoma (DLBCL) with impending airway compromise presents an urgent management dilemma, particularly when diagnostic confirmation and timely initiation of definitive therapy must be balanced against the risk of abrupt airway deterioration. Evidence guiding airway-first management before polatuzumab vedotin-containing frontline therapy remains limited.

Case presentation: We describe two older men with bulky cervical DLBCL who presented with progressive airway-related symptoms and marked upper airway narrowing on endoscopic and radiologic evaluations. In both cases, semiurgent tracheostomy was prioritized over emergent radiotherapy or immediate systemic therapy, allowing pathological confirmation and treatment planning under controlled conditions. After DLBCL was pathologically confirmed, full-dose polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) were initiated 15 and 10 days after tracheostomy, respectively, and delivered without dose reduction or treatment delay. No perioperative or tracheostomy-site complications occurred. Both patients completed six cycles of Pola-R-CHP followed by two cycles of rituximab. One patient achieved a partial metabolic response; after receiving salvage chemoimmunotherapy followed by CD19-directed chimeric antigen receptor T-cell therapy, he achieved a complete metabolic response. In the other patient, residual fluorodeoxyglucose uptake without corresponding structural lesions was managed with close surveillance after negative follow-up evaluations, including laryngoscopy and thyroid fine-needle aspiration.

Conclusions: Although limited to two patients, these cases suggest that proactive airway stabilization can create a controlled window for diagnosis and treatment planning and may facilitate safe delivery of full-dose Pola-R-CHP in selected patients with airway-threatening cervical DLBCL.

在含维多汀的Polatuzumab治疗危及气道的颈部弥漫性大b细胞淋巴瘤前进行气管造口术:2例患者报告
背景:体积较大的颈部弥漫性大b细胞淋巴瘤(DLBCL)伴气道损害迫在眉睫,面临着迫切的治疗困境,特别是当诊断确认和及时开始最终治疗必须与气道突然恶化的风险相平衡时。在含polatuzumab vedotin的一线治疗前指导气道优先管理的证据仍然有限。病例介绍:我们描述了两名老年男性大体积颈部DLBCL患者,他们在内镜和放射学评估中表现出进行性气道相关症状和明显的上呼吸道狭窄。在这两种情况下,半紧急气管切开术优先于紧急放疗或立即全身治疗,允许在受控条件下进行病理确认和治疗计划。病理证实DLBCL后,分别在气管造口术后15和10天开始全剂量的polatuzumab vedotin、利妥昔单抗、环磷酰胺、阿霉素和泼尼松(Pola-R-CHP)治疗,并且不减少剂量或延迟治疗。无围手术期及气管造口并发症发生。两名患者均完成了6个周期的Pola-R-CHP治疗,随后进行了2个周期的利妥昔单抗治疗。一名患者实现了部分代谢反应;在接受补救性化学免疫治疗和cd19靶向嵌合抗原受体t细胞治疗后,他获得了完全的代谢反应。在另一名患者中,没有相应的结构性病变的残留氟脱氧葡萄糖摄取在阴性随访评估(包括喉镜检查和甲状腺细针穿刺)后密切监测。结论:虽然只有2例患者,但这些病例表明,主动气道稳定可以为诊断和治疗计划创造一个可控的窗口,并可能促进对气道威胁的颈部DLBCL患者安全给予全剂量Pola-R-CHP。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
51
审稿时长
13 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书